• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PTC Therapeutics Inc.

    2/14/24 3:50:41 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTCT alert in real time by email
    SC 13G 1 armistice-ptct123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    PTC THERAPEUTICS, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    69366J200

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  69366J200
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,864,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,864,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,864,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.10%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  69366J200
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    6,864,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    6,864,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,864,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.10%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 69366J200
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    PTC THERAPEUTICS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    100 Corporate Court

    South Plainfield, NJ 07080

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, $0.001 par value per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    69366J200

     

    CUSIP No.  69366J200
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 69366J200
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2023:

    Armistice Capital, LLC - 6,864,000

    Steven Boyd - 6,864,000  

    (b) Percent of Class as of December 31, 2023:

    Armistice Capital, LLC - 9.10%

    Steven Boyd - 9.10% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 6,864,000

    Steven Boyd - 6,864,000 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 6,864,000

    Steven Boyd - 6,864,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 75,463,145 Shares outstanding as of October 24, 2023, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on October 26, 2023.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 69366J200
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 69366J200
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $PTCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTCT

    DatePrice TargetRatingAnalyst
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    5/7/2025$40.00Sell → Neutral
    Citigroup
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    3/7/2025$55.00Sector Perform
    Scotiabank
    12/13/2024$45.00 → $67.00Equal-Weight → Overweight
    Morgan Stanley
    12/3/2024$39.00 → $63.00Sector Perform → Outperform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    9/4/2024$44.00Outperform
    Robert W. Baird
    More analyst ratings

    $PTCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      – Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.  "Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year r

      5/6/25 4:01:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC518 PIVOT-HD Study Achieves Primary Endpoint

      - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disea

      5/5/25 7:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WARREN, N.J., May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on April 

      5/1/25 4:30:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Financials

    Live finance-specific insights

    See more
    • PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      – Strong revenue performance of $190 million –  – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date –  – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025.  "Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year r

      5/6/25 4:01:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC518 PIVOT-HD Study Achieves Primary Endpoint

      - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J., May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disea

      5/5/25 7:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

      WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investors

      4/17/25 8:00:00 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    SEC Filings

    See more
    • SEC Form 10-Q filed by PTC Therapeutics Inc.

      10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/6/25 4:34:25 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/6/25 4:03:36 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

      5/5/25 7:55:12 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gravier Pierre bought $198,736 worth of shares (7,700 units at $25.81), increasing direct ownership by 30% to 33,700 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      12/14/23 4:38:32 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $PTCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $136,656 worth of shares (2,804 units at $48.74), decreasing direct ownership by 1% to 273,234 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      4/24/25 5:20:05 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold $42,114 worth of shares (897 units at $46.95), decreasing direct ownership by 1% to 75,997 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      4/4/25 5:20:04 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF BUSINESS OFFICER Pauwels Eric sold $630,104 worth of shares (11,220 units at $56.16), decreasing direct ownership by 13% to 72,640 units (SEC Form 4)

      4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

      3/18/25 5:20:05 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PTC Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00

      5/9/25 8:40:13 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded PTC Therapeutics from Sell to Neutral and set a new price target of $40.00

      5/7/25 8:34:42 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PTC Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded PTC Therapeutics from Underperform to Neutral and set a new price target of $55.00 from $41.00 previously

      3/11/25 7:43:05 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      11/14/24 5:22:11 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      11/8/24 10:52:39 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

      SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

      10/18/24 10:57:11 AM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PTCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

      SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein

      7/17/23 4:30:00 PM ET
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care